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ABSTRACT
Objective To determine the relative benefits and risks of
laparoscopic fundoplication surgery as an alternative to
long term drug treatment for chronic gastro-oesophageal
reflux disease (GORD).
Design Multicentre, pragmatic randomised trial (with
parallel preference groups).
Setting 21 hospitals in the United Kingdom.
Participants 357 randomised participants (178 surgical,
179medical)and453preferenceparticipants(261,192);
meanage46;66%men.Allparticipantshaddocumented
evidence of GORD and symptoms for >12 months.
InterventionThetypeoflaparoscopicfundoplicationused
was left to the discretion of the surgeon. Those allocated
to medical treatment had their treatment reviewed and
adjusted as necessary by a local gastroenterologist, and
subsequent clinical management was at the discretion of
the clinician responsible for care.
Main outcome measures The disease specific REFLUX
qualityof lifescore (primaryoutcome),SF-36, EQ-5D,and
medication use, measured at time points equivalent to
three and 12 months after surgery, and surgical
complications.
MainresultsRandomisedparticipantshadreceiveddrugs
for GORD for median of 32 months before trial entry.
BaselineREFLUXscoreswere63.6(SD24.1)and66.8(SD
24.5) in the surgical and medical randomised groups,
respectively. Of those randomised to surgery, 111 (62%)
actually had total or partial fundoplication. Surgical
complications were uncommon with a conversion rate of
0.6% and no mortality. By 12 months, 38% (59/154)
randomised to surgery (14% (14/104) among those who
had fundoplication) were taking reflux medication versus
90% (147/164) randomised medical management. The
REFLUX score favoured the randomised surgical group
(14.0, 95% confidence interval 9.6 to 18.4; P<0.001).
Differences of a third to half of 1 SD in other health status
measures also favoured the randomised surgical group.
Baseline scores in the preference for surgery group were
the worst; by 12 months these were better than in the
preference for medical treatment group.
Conclusion At least up to 12 months after surgery,
laparoscopic fundoplication significantly increased
measures of health status in patients with GORD.
Trial registration ISRCTN15517081.
INTRODUCTION
Gastro-oesophageal reflux disease (GORD) causes
some of the most commonly seen symptoms in both
primary and secondary care.
1 Most have only mild
symptoms and require little if any medication. A small
minority have severe reflux and, despite full medical
treatment, have complications or persistent symptoms
requiring surgical intervention. For the remainder,
control of symptoms requires regular or intermittent
medical treatment, usually with proton pump inhibi-
tors, and it is from this intermediate group that most of
thetreatmentcostsarise.Whilethereiswideagreement
that proton pump inhibitors, sometimes combined
withprokineticagents,arethemosteffectivetreatment
for moderate to severe GORD, they can cause a
spectrum of short term symptoms,
2 and there are
concerns about the impact of long term use through
profound acid suppression.
3
Interest in surgery as an alternative to long term
medical treatment has been considerable since the
introduction of the minimal access laparoscopic
approach in the early 1990s. The operation (fundopli-
cation) involves partial or total wrapping of the fundus
of the stomach around the lower oesophagus to
recreateahighpressurezone.Althoughfundoplication
producesresolutionofrefluxsymptomsinupto90%of
patients,
4 we do not know whether exchanging
symptoms associated with best medical management
for those of the side effects of surgery is advantageous
for the patient and a good use of healthcare resources.
We carried out a multicentre pragmatic randomised
trial (with parallel non-randomised preference groups
to contextualise the results and augment them,
particularly in respect of surgical complications),
5
evaluating the clinical effectiveness, safety, and costs
of a policy of relatively early laparoscopic surgery
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GORD for people judged suitable for both policies.
METHODS
Participants
Patientswereeligibleiftheyhadmorethan12months’
symptoms requiring maintenance treatment with a
proton pump inhibitor (or alternative) for reasonable
control; they had endoscopic or 24 hour pH monitor-
ingevidenceofGORD,orboth;theyweresuitablefor
either policy (including American Society of Anesthe-
siologists(ASA)gradeIorII);andtherecruitingdoctor
was uncertain which management policy to follow.
Exclusion criteria were morbid obesity (BMI >40);
Barrett’s oesophagus of more than 3 cm or with
evidence of dysplasia; para-oesophageal hernia; and
oesophageal stricture.
We invited any eligible patient who did not want to
take part in the randomised trial because of a strong
preference about treatment to join a non-randomised
preference arm. An independent data monitoring
committee recommended continued recruitment on
each of the three occasions that it confidentially
reviewed accumulating data.
Clinical management
Clinicalmanagementaimedtooptimisecurrentcarein
participating centres. Participating clinical centres had
local partnerships between surgeons (who had per-
formed at least 50 laparoscopic fundoplication opera-
tions) and gastroenterologists with whom they shared
the secondary care of patients with GORD. They,
supported by local research nurses, informed partici-
pants about the randomised trial and invited them to
takepart.Itwasonlyatthispointthatparticipantswho
declinedtotakepartintherandomisedtrial,becauseof
a strong preference either for remaining on medical
treatment or for undergoing surgery, were informed
about, and given the opportunity to take part in, the
preference study.
For all participants in either the randomised or
preference surgical group, surgery could be subse-
quently deferred or declined, by either the participant
orsurgeon(thatis,evenaftertrialentry).Intheabsence
of erosive oesophagitis on endoscopy, and when
necessary to exclude achalasia, manometry or pH
studieswereperformedbeforesurgery.Aleadsurgeon
(or a less experienced surgeon working under super-
vision) undertook the surgery. Routine crural repair
and non-absorbable synthetic sutures were recom-
mended. The type of fundoplication was left to the
discretionofthesurgeon,whorecordedintraoperative
details on a specially designed study form. For the
purposes of the main comparisons, we considered the
different fundoplication techniques as a single policy.
Those allocated to medical treatment had their
treatment reviewed and adjusted as necessary by a
local gastroenterologist to be “best medical manage-
ment,” based on the Genval workshop report.
6 The
medical protocol included the option of surgery if a
clear indication developed after randomisation. In all
Ineligible (n=200)
Eligible but not recruited (n=68)
Assessed for eligibility (n=1078)
Patients randomised (n=357) Patients in preference study (n=453)
Allocated to surgery (n=178):
Withdrawn before surgery (n=20)
Received surgery (n=111)
Declined surgery (n=47)
Allocated to medicine (n=179):
Received surgery (n=10)
Preference surgery (n=261):
Withdrawn before surgery (n=16)
Received surgery (n=218)
Declined surgery (n=25)
Surgery deferred (n=2)
Preference medicine (n=192):
Received surgery (n=3)
 Baseline questionnaire 
returned (n=175)
Baseline questionnaire returned 
(n=174)
 Baseline questionnaire returned 
(n=256)
 Baseline questionnaire returned 
(n=189)
Follow-up at time equivalent to 
1 year after surgery (n=154)
Withdrawn/lost to follow-up (n=14)
 Response (n=154)
Non-response (n=10) 
Analysed with Reflux QoL score 
(n=145)
Follow-up at time equivalent to 
1 year after surgery (n=164)
Withdrawn/lost to follow-up (n=5)
Death (n=1)
 Response (n=164)
Non-response (n=9)
 
Analysed with Reflux QoL score 
(n=154)
Follow-up at time equivalent to 
1 year after surgery (n=230)
Withdrawn/lost to follow-up (n=12)
Death (n=2)
 Response (n=230)
Non-response (n=17)
Analysed with Reflux QoL score 
(n=212)
Follow-up at time equivalent to 
1 year after surgery (n=177)
Withdrawn/lost to follow-up (n=8)
 Response (n=177)
Non-response (n=7)
 Analysed with Reflux QoL score 
(n=163)
Flow of participants through trial
RESEARCH
page 2 of 8 BMJ | ONLINE FIRST | bmj.comother respects, clinical management was at the discre-
tion of the clinician responsible for care.
Outcome measures
Outcome measures were those judged important to
patientsandhealthservices.Theprimaryoutcomewas
theREFLUXquestionnairescore,avalidated“disease
specific” measure incorporating assessment of reflux
and other gastrointestinal symptoms and the side
effects and complications of both treatments (score
range 0 to 100, the higher the score the better the
patientsfelt).
7Thescorewasderivedfromtheweighted
average of six questions on quality of life (heartburn;
acidreflux;eatingandswallowing;bowelmovements;
sleep; and work, physical, and social activities). Five
symptom scores were also developed as secondary
measures (general discomfort; wind and frequency;
nausea and vomiting; limitation in activity; constipa-
tionandswallowing).Participantswerefollowedupby
postalquestionnairethreeand12monthsaftersurgery
oratanequivalenttimeamongthosewhodidnothave
surgery; the medical participants were linked to
surgical participants who had been randomised at
about the same time. Issues related to long, variable
length, waiting lists prohibited timing of follow-up
from randomisation. Other prestated outcome mea-
sures were health status (EQ-5D, based on UK public
preference values, and SF-36); serious morbidity, such
as operative complications; and mortality.
Sample size
We originally intended to recruit 300 participants to
each trial group to identify a difference between the
randomised groups of 0.25 of 1 SD in the disease
specific REFLUX score (80% power; α=0.05)
12 months after surgery. In January 2003, however,
in part prompted by a lower rate of recruitment than
expected,werevisedthistargetinconsultationwiththe
data monitoring committee and representatives of the
funders. It was agreed that a slightly larger but still
moderatesizedbenefit(0.3of1SD,equivalenttoseven
points on the REFLUX quality of life score) was
clinicallyplausiblebasedonimprovementsreportedin
other studies
89 after surgery among more severely
affectedpeople.Wecalculatedthatthisrequired196in
eachgrouptogive80%power(α=0.05),assuming10%
attrition (that is, 176 per group with 12 month follow-
up).
Randomisation
Randomallocationwasorganisedcentrallybyasecure
system, using a computer generated sequence, strati-
fiedbyclinicalsite,withbalanceinrespectofage(18-49
or ≥50), sex (men or women), and BMI (≤28 or >29)
securedbyminimisation.Staffinthecentraltrialoffice
entered details of participants on the secure database,
thennotifiedparticipantsandrespectiveclinicalsitesof
their allocation. There was no subsequent blinding.
Thefiguresummarisesthestagesofthetrial.Thefirst
146 randomised participants (70 allocated to surgery
and 76 allocated to medical management) were sent
details of their allocation at the same time as the
baseline questionnaires. This was changed at the
request of the data monitoring committee such that
subsequent allocations were generated only once
completed baseline forms had been returned. The
committee were concerned that if patients were to
receive their allocation before completing the ques-
tionnaire this could potentially affect their responses.
Statistical methods
Our primary analysis in the randomised trial was by
intention to treat. General linear models adjusted for
the minimisation covariates (age, BMI, and sex) and,
when appropriate, for baseline score and interaction
between baseline score and treatment. We also
includedacovariatetoadjustforthechangeinpractice
regarding the baseline questionnaires. All analyses
used 95% confidence intervals. Because a relatively
large proportion of the randomised surgical partici-
pants did not receive surgery, we also performed per
protocol analyses and analyses adjusted for treatment
received
1011 to estimate efficacy of treatment. For the
preference groups, we analysed statistically only the
primary outcome, the REFLUX score. This analysis
compared the group who preferred surgery with the
group who preferred medical treatment and adjusted
for the minimisation factors. We did not plan to adjust
Table 1 |Description of groups at trial entry. Figures are number (percentage*) unless stated otherwise
Randomised participants Preference participants
Surgical Medical Surgical Medical
ITT (n=178) PP (n=111) ITT (n=179) PP (n=169) ITT (n=261) PP (n=218) ITT (n=192) PP (n=189)
Baseline questionnaire returned 175 (98) 111 (100) 174 (97) 165 (98) 256 (98) 216 (99) 189 (98) 186 (98)
Mean (SD) age (years) 46.7 (10.3) 46.3 (10.2) 45.9 (11.9) 45.9 (11.9) 44.4 (12.0) 44.5 (12.2) 49.9 (11.8) 50 (11.7)
Men 116 (65) 68 (61) 120 (67) 115 (68) 170 (65) 139 (64) 111 (58) 110 (58)
Mean (SD) BMI 28.5 (4.3) 28.7 (4.1) 28.4 (4.0) 28.3 (4.0) 27.7 (4.0) 27.5 (3.7) 27.4 (4.1) 27.4 (4.1)
Median duration (months) of prescribed
medication for GORD (IQR)
33 (15-83) 30 (16-76) 31 (16-71) 30 (15-71) 35 (14-71) 36 (14-65) 27 (13-60) 26.5 (13-60)
In full time paid employment 116 (66) 72 (66) 110 (62) 104 (62) 168 (65) 138 (64) 100 (52) 97 (52)
C u r r e n ts m o k e r 4 6( 2 6 ) 2 9( 2 6 ) 4 0( 2 2 ) 3 6( 2 1 ) 7 1( 2 7 ) 6 1( 2 8 ) 3 9( 2 0 ) 3 9( 2 1 )
ITT=intention to treat; PP=per protocol; BMI=body mass index; IQR=interquartile range.
*Calculated excluding missing data from returned forms.
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methodsin the analysisof the preference groups given
the anticipated non-random imbalances at baseline.
RESULTS
Recruitment took place in 21 centres in the United
Kingdom from March 2001 to June 2004: 357
participantswereintherandomisedarm(178allocated
tosurgeryand179tomedicalmanagement)and453in
the preference arm (261 chose surgery and 192 chose
medical management) (figure). The three and
12 month follow-ups were conducted an average of
86and360daysaftersurgery,respectively,andthiswas
equivalentto300and570days(580and540daysinthe
randomisedsurgicalandmedicalgroups,respectively)
after randomisation across all the trial groups; three
and 12 month follow-up questionnaires were received
from 86% and 89% participants, respectively. Three
participants died, two in the preference for surgery
groupandoneintherandomisedmedicalgroup;none
had surgery. All deaths were unrelated to trial
participation.
Description of the groups at trial entry
The characteristics of the randomised participants
(table 1, baseline rates for medication in table 2, and
table A on bmj.com) were similar and lay between
those in the preference groups; participants in the
preference for surgery group were younger and had
been prescribed medication for GORD for longer;
participants in the preference for medical treatment
group were older, more likely to be women, and had
been prescribed medication for a shorter time.
Surgical management
In total, 111 (62%) of those randomised to surgeryand
218 (84%) participants in the preference for surgery
group actually received fundoplication (table 3). The
most common clinical reasons for not having surgery
were a surgeon’s decision that symptoms were not
sufficiently severe or that a patient was not fit for
surgery(suchasbeingoverweight).Themostcommon
personalreasonswereparticipants’changeofmindfor
workorhomerelatedreasons,concernsaboutsurgery,
a wish to avoid preoperative tests, and improved
symptoms.
Table 3showsdetailsofthesurgery.Two(1%)ofthe
329 participants who had surgery had conversions to
an open procedure (95% confidence interval 0.2% to
2.2%), and eight (2%) had a visceral injury (1.2% to
4.7%). Most of those who had fundoplication were
dischargedhomewithintwodays.Three(1%)required
reoperation(0.3%to2.6%)—allinthepreferencegroup
—and three had dilatation of an oesophageal stricture
or for food disimpaction within 12 months of their
initial surgery.
Antireflux medication
Table 2 also showsactual use of antireflux medication
during the previous two weeks at baseline, first follow-
Table 2 |Use of antireflux medication in previous two weeks. Figures are number (percentage*) unless stated otherwise
Randomised participants Preference participants
Surgical Medical Surgical Medical
ITT (n=178) PP (n=111) ITT (n=179) PP (n=169) ITT (n=261) PP (n=218) ITT (n=192) PP (n=189)
Taking any drug related to reflux
Baseline 170 (97) 108 (97) 169 (97) 160 (97) 235 (92) 198 (92) 184 (97) 181 (9)
3 months after surgery 50 (33) 10 (9) 146 (92) 139 (93) 45 (20) 17 (8) 176 (97) 161 (90)
12 months after surgery 59 (38) 15 (14) 147 (90) 144 (93) 46 (20) 22 (11) 165 (93) 163 (94)
Taking any proton pump inhibitors
Baseline 161 (92) 105 (95) 162 (93) 153 (93) 225 (88) 191 (88) 173 (92) 170 (91)
3 months after surgery 47 (31) 8 (7) 140 (89) 133 (89) 41 (18) 13 (6) 167 (92) 152 (85)
12 months after surgery 56 (36) 13 (13) 142 (87) 139 (90) 42 (18) 19 (9) 156 (88) 154 (89)
ITT=intention to treat; PP=per protocol.
*Calculated excluding missing data from returned forms.
Table 3 |Details of surgery for gastro-oesophageal reflux disease. Figures are number
(percentage) unless stated otherwise
Surgical participants
Randomised (n=178) Preference (n=261)
Received surgery 111 (62) 218 (84)
Declined surgery for clinical reasons 25 (14) 13 (5)
Declined surgery for personal reasons 22 (12) 11 (4)
Other/withdrawn/lost to follow-up before surgery 20 (11) 19 (7)
Management of those who actually had surgery
Type of fundoplication*:
Total wrap 52 (47) 158 (73)
Partial-anterior 51 (46) 35 (16)
Partial-posterior 8 (7) 24 (11)
Grade of operating surgeon†:
Consultant 100 (92) 174 (81)
Other 9 (8) 42 (19)
Mean (SD) operation time (mins) 113 (38) 123 (64)
Conversion 2 (2) 0 (0)
Visceral injury 2 (2) 6 (3)
Reoperation within 12 months 0 (0) 3 (1)
Stricturedilatationorfooddisimpactionrequiredwithin
12 months
1( 1 ) 2( 1 )
Median (IQR) length of stay (days) 2 (2-3) 2 (2-3)
IQR=interquartile range.
* Data missing for one patient in preference group.
†Data missing for two patients in randomised group and two in preference group.
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38% (59/154) of the randomised surgical participants
weretakingmedicationcomparedwith90%(147/164)
of the randomised medical participants (nearly all of
whom were taking proton pump inhibitors). Among
those who had surgery, use of antireflux medication
dropped to 9% at three months and 14% (14/104) at
12monthsaftersurgery.Improvementsinthescoresin
the medical group might reflect changes in manage-
ment;lansoprazolewasthepredominantprotonpump
inhibitor used at study entry, whereas at follow-up
omeprazole and lansoprazole were the most com-
monly reported.
Health status
Table 4showsREFLUXscoresatbaselineandatthree
and 12 months (see also tables B and C on bmj.com).
There were substantial differences between the rando-
misedintentiontotreatgroupsintheREFLUXscore(a
third to a half of 1 SD at follow up), with the surgery
group having better scores than the medical group.
This reflected improvements across all symptom
domainswithin the measure (seetables B,C,and D on
bmj.com).Thedifferencesbetweengroupswerelarger
whenweconsideredonlytheperprotocolparticipants.
Statistical analyses for the primary outcome
(REFLUX score 12 months after surgery) showed
strong evidence of increases in scores favouring
surgery (table 5). Both the per protocol analyses and
analyses adjusted for treatment received (providing
estimates of treatment efficacy) suggested larger
differences between the randomised groups. For the
intention to treat analysis, the mean difference in
favour of surgery was 11.2 between the groups with
adjustmentforonly theminimisationvariables(model
I) and this increased to 14.1 when we included the
baselinescore(modelII).Therewasstrongevidenceof
an interaction effect between randomised group and
baseline REFLUX score (interaction term: −0.35,
−0.53to−0.17;P<0.001).Thisimpliedthatasbaseline
REFLUX score decreased (baseline symptoms were
more severe) the treatment effect of surgery increased.
For example, estimating the treatment difference at
baselinemeanREFLUXscoreof65.4resultedinatrial
effect size of 14.0 (9.6 to 18.4; P<0.001; model III, the
mostparsimoniousmodel).Iftheaveragepatienthada
lower mean REFLUX score at baseline of 56.0, the
effectsizeincreasedto17.2(12.6to21.9).Ifthepatient
hadahigherbaselinescoreof78.0,thetreatmenteffect
decreased to 9.5 (4.5 to 14.5).
Similarpatternsintherandomisedgroupswereseen
in the SF-36 scores, where the biggest differences
favouring surgery were observed in the general health
and bodily pain dimensions and in the EQ-5D score
(see tables B, C, and D on bmj.com), although with
some evidence of attenuation at 12 months. Three
participantsdied,oneintherandomisedmedicalgroup
(roadtrafficincident)andtwointhepreferencesurgical
group, neither of whom had surgery (alcoholic liver
disease and cause unknown).
Possible side effects of surgery
No differences were detected between the trial groups
in their questionnaire responses at 12 months regard-
ing “difficulty swallowing” and “bloatedness/trapped
wind,” but there was some evidence of more frequent
“wind from the lower bowel” after surgery.
Preference groups
The participants in the preference for surgery group
hadlowermeanREFLUXscoresatbaselinethanthose
in the preference for medical treatment group (55.8 v
77.5). Despite this, at follow-up at 12 months, accord-
ing to intention totreat analysis(difference 3.9, −0.2 to
8.0;P=0.064)andperprotocolanalysis(6.3,2.4to10.2;
P=0.002) the REFLUX score favoured the preference
surgical group.
For participants in the preference group, other
quality of life scores also tended to favour the surgical
group.Thedifferencesbetweenthepreferencegroups,
however, were less marked than the differences
between the randomised groups, mainly because the
preference for medical treatment group had better
scores than the randomised medical group at baseline
and follow-up.
DISCUSSION
Principal findings
In patients with GORD, laparoscopic fundoplication
results in better symptom relief and improved quality
Table 4 |Health status at baseline and at three and 12 months after surgery. Figures are means (SD)
Randomised participants Preference participants
Surgical Medical Surgical Medical
Randomised
(n=178)
Per protocol
(n=111)
Randomised
(n=179)
Per protocol
(n=169)
Preference
(n=261)
Per protocol
(n=218)
Preference
(n=192)
Per protocol
(n=189)
Primary outcome (REFLUX QoL)
Baseline 63.6 (24.1) 61.9 (24.5) 66.8 (24.5) 68.2 (24.2) 55.8 (23.2) 55.9 (23.2) 77.5 (19.7) 78.0 (19.1)
3 months 83.9 (19.4) 85.9 (19.0) 70.6 (24.6) 70.8 (24.4) 80.4 (21.6) 82.5 (20.3) 80.2 (18.2) 80.6 (17.7)
12 months 84.6 (17.9) 88.3 (15.6) 73.4 (23.3) 73.1 (23.7) 83.3 (20.7) 86.0 (17.9) 79.2 (19.2) 79.4 (19.0)
Secondary outcome (EQ-5D index)
Baseline 0.71 (0.26) 0.72 (0.24) 0.72 (0.25) 0.73 (0.25) 0.68 (0.26) 0.68 (0.26) 0.75 (0.22) 0.75 (0.22)
3 months 0.79 (0.23) 0.81 (0.24) 0.69 (0.30) 0.70 (0.30) 0.81 (0.25) 0.82 (0.24) 0.76 (0.23) 0.77 (0.23)
12 months 0.75 (0.25) 0.78 (0.23) 0.71 (0.27) 0.71 (0.27) 0.79 (0.26) 0.80 (0.25) 0.74 (0.24) 0.74 (0.24)
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There were highly significant differences between the
randomised groups in the REFLUX scores three
months after surgery (a half to a third of 1 SD)
favouring surgery, and these were broadly sustained
nine months later. The lower the REFLUX scores at
entry—that is, the worse the symptoms—the larger
were the improvements after surgery. Similar differ-
enceswereseeninmostoftheothermeasuresofhealth
status. There was, however, some evidence of a
narrowing of the differences between three and
12 months, particularly for the EQ-5D. Data on drug
treatment were consistent with this, showing more use
in the surgical groups at 12 months than at three
months. There were small improvements in scores in
the medical groups; this might reflect their having
specialist review at trial entry to optimise their drug
treatment.
Those who agreed to join the randomised trial had
baseline characteristics between the two preference
groups. The results in the preference groups were
consistent with the randomised comparison: scores
after surgery in those who preferred surgery were
somewhat higher than in those who preferred medical
treatment, despite starting from much lower baseline
levels. None of the three participants who died had
surgery and complications were uncommon; but
confidence intervals around estimated frequencies
were wide despite inclusion of all 319 surgical
participants, leaving important uncertainty about the
magnitude of surgical risk.
Strengths and weaknesses
We used a pragmatic trial design, with many UK
patients, centres and experienced surgeons, thus
allowing the results to be interpreted within a “real
life” NHS context. The addition of the preference
groups gives an indication of probable behaviour if
surgery were to become more freely available.
We explored the impact of a third of those
randomised to surgery not having fundoplication:
firstly, through per protocol analyses limited to those
randomisedwhoreceivedtheirallocatedmanagement,
and, secondly, through an adjusted approach
1011 in an
attempt to circumvent the probable selection bias of
per protocol analyses. In the event, these two
approachesgavesimilarresults.Thedirectionofeffects
was so clear that we observed significant differences
even in the most conservative intention to treat
analyses.Whilethe intentiontotreatanalysesestimate
unbiased average effects on compliers and non-
compliers,theadjustedanalysesestimatebiasadjusted
average treatment effects on those who comply with
treatment.Ingeneral,anadjustedanalysisispreferable
toaperprotocolanalysisasitislesslikelytobebiased.
The protocol allowed surgeons to use the type of
fundoplication with which they were familiar, princi-
pally to avoid any learning effects. There is mixed
evidence for the use of a total wrap or partial wrap.
12
Weexploredpossibledifferentialeffectsoftotalversus
partial wrap fundoplication in an observational analy-
sis and found no evidence of a difference within either
the randomised, preference, or per protocol groups
(difference in 12 month REFLUX score −1.3 (−7.9 to
5.2), P=0.687).
Our study was limited to patients who were on long
term acid suppression with proton pump inhibitors,
who had symptoms that were reasonably controlled,
andwhowereclinicallysuitableforeitherpolicy;itisto
these sorts of patients with GORD that the results are
generalisable. Potential participants were not easy to
identify and recruit, and this led to slow recruitment.
Most patients taking long term proton pump inhibitor
treatment are managed in general practice, often
through a repeat prescription system, whereas our
trial was based in secondary care. We used three
approaches to identify potentially eligible patients:
retrospectivereviewofhospitalcasenotes;prospective
identification, especially through endoscopy clinics;
and (in selected centres) public advertisements. All
potentially eligible patients then had to be assessed
clinically, often through specially established monthly
clinics, before being formally approached about the
trial. Those approached often expressed clear prefer-
ences, reflecting the marked differences between the
policies being compared.
The trial was conducted at a time when there was
great pressure on surgical services in the NHS, with
longdelaysforelectivesurgeryfornon-lifethreatening
benign conditions. Indeed, the average time between
trialentryandsurgerywaseighttoninemonths.Some
participants experienced long delays before being
formally offered surgery, and this was an important
factor in their eventual decision to choose not to have
surgery after all. While patient’s choice was the
commonest reason for not having surgery, about a
third of those who did not have fundoplication after
allocation to surgery were refused surgery for clinical
Table 5 |Difference* (95% confidence interval) in REFLUX quality of life score† at 12 months after surgery in randomised
participants
Model Intention to treat Per protocol Adjusted for treatment received
I: adjusted for minimisation variables 11.2 (6.4 to 16.0) 15.4 (10.0 to 20.9) 16.7 (9.7 to 23.6)
II: adjusted for minimisation variables and baseline
REFLUX QoL score
14.1 (9.6 to18.6) 19.1 (14.0 to 24.1) 20.3 (13.8 to 26.8)
III: adjusted for minimisation variables, baseline score, and
interaction between treatment and baseline REFLUX QoL score
14.0 (9.6 to18.4) 18.4 (13.6 to 23.2) 19.4 (13.0 to 25.8)
*Surgery group minus medical group, all P<0.001.
†Higher scores mean patient felt better (range 0-100).
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the recruiting doctor that symptoms were sufficient to
justify surgery or judged that the patient was not
sufficiently fit (such as overweight) or the symptoms
had improved since randomisation,
The standard rule in most trials is to time follow-up
from randomisation. This was not appropriate in our
trial because of the variable time between randomisa-
tion and surgery, exacerbated by the waiting list
problem. The protocol specified follow-up at a time
equivalent to threeand 12 months aftersurgery.It was
importanttohavefollow-upinthemedicalgroupsatan
equivalenttime.Wearrangedthisbysettingthefollow-
up of medical participants at time points equivalent to
three months and 12 months after surgery.
We focused directly on subjective measures of
outcome (patient reported measures) rather than on
objective measures of outcome. This was intentional
and appropriate for the pragmatic evaluation of the
interventions. In clinical practice, pH is not routinely
measured after surgery. If we had included such
objective outcome measures, this would have entailed
our changing the regular management practices for
these patients, thus jeopardising the generalisability of
both our intervention and our findings.
Comparison with other studies
We identified two other randomised trials comparing
laparoscopic Nissen fundoplication with continued
medical management.
1314 They were less pragmatic in
design with fewer participants (217
13 and 104
14),
centres (two
13 and one
14), and surgeons (two
13 and
four
14) and reported postoperative 24 hour pH
measurement. The results of the two trials were
consistent with ours. Across all trials, there were
significantly greater improvements after surgery in
measures of gastrointestinal and general wellbeing.
While no major intraoperative complications were
reportedamongthe52patientswhohadsurgeryinone
trial,
14 in the other trial there were four major
complications and four reoperations, including one
case of gastric resection, among the 109 patients who
had fundoplication,
13 illustrating the potential risks of
the procedure.
Conclusions
Laparoscopic fundoplication significantly increased
healthstatusatleastto12monthsaftersurgery.Surgery
does carry costs, however, and we will report
investigation of cost effectiveness elsewhere. The
narrowing of differences in health status between
three and 12 months could reflect a postoperative
placebo effect or could indicate decreasing effective-
ness of surgery over time from surgery (as has been
observed after open fundoplication
9). We have there-
fore instituted annual follow-up using similar ques-
tionnaires and plan to report long term effectiveness
after five years of follow-up.
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